IS6362A - Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni - Google Patents

Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni

Info

Publication number: IS6362A
Authority: IS; Iceland
Prior art keywords: urea; compounds; receptor antagonist; antagonist activity; muscarinic receptor
Prior art date: 1999-12-07

Application number

IS6362A

Other languages

English (en)

Other versions

IS2191B (is

Inventor

Mammen Mathai

Oare David

Original Assignee

Theravance, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-12-07

Filing date

2002-04-26

Publication date

2002-04-26

2002-04-26 Application filed by Theravance, Inc. filed Critical Theravance, Inc.

2002-04-26 Publication of IS6362A publication Critical patent/IS6362A/is

2007-01-15 Publication of IS2191B publication Critical patent/IS2191B/is

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/48—Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/08—Bridged systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/08—Bridged systems

Landscapes

Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Urology & Nephrology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Ophthalmology & Optometry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Hydrogenated Pyridines (AREA)
Plural Heterocyclic Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

IS6362A 1999-12-07 2002-04-26 Þvagefnisefnasambönd sem hafa múskarínviðtaka mótlyfsvirkni IS2191B (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US45617099A	1999-12-07	1999-12-07
PCT/US2000/033155 WO2001042213A1 (en)	1999-12-07	2000-12-07	Urea compounds having muscarinic receptor antagonist activity

Publications (2)

Publication Number	Publication Date
IS6362A true IS6362A (is)	2002-04-26
IS2191B IS2191B (is)	2007-01-15

Family

ID=23811737

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6362A IS2191B (is)	1999-12-07	2002-04-26	Þvagefnisefnasambönd sem hafa múskarínviðtaka mótlyfsvirkni

Country Status (27)

Country	Link
US (3)	US6635764B2 (is)
EP (2)	EP1457488B1 (is)
JP (1)	JP2003516391A (is)
KR (1)	KR100748150B1 (is)
CN (1)	CN1271054C (is)
AT (2)	ATE439345T1 (is)
AU (1)	AU782232B2 (is)
BR (1)	BR0015963A (is)
CA (1)	CA2392030C (is)
CZ (1)	CZ20021830A3 (is)
DE (2)	DE60042762D1 (is)
EA (1)	EA006437B1 (is)
ES (3)	ES2225275T3 (is)
HK (1)	HK1049483B (is)
HR (1)	HRP20020574B1 (is)
HU (1)	HUP0203677A2 (is)
IL (2)	IL149289A0 (is)
IS (1)	IS2191B (is)
MX (1)	MXPA02005602A (is)
NO (1)	NO323544B1 (is)
NZ (1)	NZ518722A (is)
PL (1)	PL364922A1 (is)
SK (1)	SK7982002A3 (is)
UA (1)	UA73543C2 (is)
WO (1)	WO2001042213A1 (is)
YU (1)	YU42402A (is)
ZA (2)	ZA200204557B (is)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
UA73543C2 (uk) *	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
GB0108099D0 (en) *	2001-03-30	2001-05-23	Hoffmann La Roche	Aminopiperidine derivatives
US20030236287A1 (en) *	2002-05-03	2003-12-25	Piotrowski David W.	Positive allosteric modulators of the nicotinic acetylcholine receptor
EP1546099B1 (en)	2002-07-08	2008-12-31	Ranbaxy Laboratories Limited	3,6-disubstituted azabicyclo 3.1.0 hexane derivatives useful as muscarinic receptor antagonists
CN100364990C (zh) *	2002-10-30	2008-01-30	施万制药	取代的4-氨基-1-(吡啶甲基)哌啶和相关化合物
TWI295669B (en) *	2002-10-30	2008-04-11	Theravance Inc	Substituted 4-amino-1-(pyridylmethyl) piperidine and related compounds
PE20040950A1 (es) *	2003-02-14	2005-01-01	Theravance Inc	DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
CN101239970B (zh) *	2003-02-14	2011-07-20	施万制药	联苯衍生物
CA2520763A1 (en) *	2003-04-03	2004-10-21	The Regents Of The University Of California	Improved inhibitors for the soluble epoxide hydrolase
US7517905B2 (en)	2003-04-09	2009-04-14	Ranbaxy Laboratories Limited	Substituted azabicyclo hexane derivatives as muscarinic receptor antagonists
WO2004089900A1 (en)	2003-04-11	2004-10-21	Ranbaxy Laboratories Limited	Azabicyclo derivatives as muscarinic receptor antagonists
KR20060065586A (ko) *	2003-06-23	2006-06-14	씨브이 쎄러퓨틱스, 인코포레이티드	지방산 산화 저해제로서의, 피페라진 및 피페리딘의 우레아유도체
EP1644356A1 (en) *	2003-07-11	2006-04-12	Theravance, Inc.	Substituted 4-amino-1-benzylpiperidine compounds
UY28538A1 (es) *	2003-09-26	2005-04-29	Vertex Pharma	Derivados de fenil-piperazina como moduladores de receptores muscarínicos
PE20050973A1 (es) *	2003-10-29	2005-11-19	Theravance Inc	Sales de acido naftalen-1,5-disulfonico de un compuesto de 4-amino-1-(piridilmetil)piperidina como antagonistas de receptores muscarinicos
US7345060B2 (en) *	2003-11-21	2008-03-18	Theravance, Inc.	Compounds having β2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7320990B2 (en)	2004-02-13	2008-01-22	Theravance, Inc.	Crystalline form of a biphenyl compound
TW200538095A (en) *	2004-03-11	2005-12-01	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7524962B2 (en) *	2004-03-11	2009-04-28	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
JP2007528415A (ja) *	2004-03-11	2007-10-11	セラヴァンス，インコーポレーテッド	ムスカリンレセプターアンタゴニストとしての有用なビフェニル化合物
WO2005087733A1 (en) *	2004-03-11	2005-09-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
TWI341836B (en) *	2004-03-11	2011-05-11	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
EP1723110A1 (en) *	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
EP1723115A1 (en)	2004-03-11	2006-11-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
WO2005087736A1 (en) *	2004-03-11	2005-09-22	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
CA2559665A1 (en)	2004-03-16	2005-09-29	The Regents Of The University Of California	Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids
AU2005245021A1 (en) *	2004-05-21	2005-12-01	The Regents Of The University Of California	Methods for treating and diagnosing cancer with wnt inhibitory factor-1 (wif-1)
TWI374883B (en)	2004-08-16	2012-10-21	Theravance Inc	Crystalline form of a biphenyl compound
EP1778626A1 (en) *	2004-08-16	2007-05-02	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
EP1833822A2 (en)	2004-08-16	2007-09-19	Theravance, Inc.	Compounds having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US7662910B2 (en)	2004-10-20	2010-02-16	The Regents Of The University Of California	Inhibitors for the soluble epoxide hydrolase
US7880007B2 (en)	2004-11-29	2011-02-01	Vertex Pharmaceuticals Incorporated	Bicyclic substituted phenyl piperidine modulators of muscarinic receptors
GB0503054D0 (en) *	2005-02-14	2005-03-23	Smithkline Beecham Corp	Chemical compounds
US7479562B2 (en) *	2005-03-10	2009-01-20	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
TWI372749B (en) *	2005-03-10	2012-09-21	Theravance Inc	Crystalline forms of a biphenyl compound
JP2008533028A (ja) *	2005-03-10	2008-08-21	セラヴァンス，インコーポレーテッド	ムスカリン性受容体アンタゴニストとして有用なビフェニル化合物
TW200714587A (en) *	2005-03-10	2007-04-16	Theravance Inc	Biphenyl compounds useful as muscarinic receptor antagonists
US7642355B2 (en) *	2005-03-10	2010-01-05	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
US7659403B2 (en) *	2005-03-10	2010-02-09	Theravance, Inc.	Biphenyl compounds useful as muscarinic receptor antagonists
WO2006105035A2 (en) *	2005-03-28	2006-10-05	Vertex Pharmaceuticals Incorporated	Muscarinic modulators
JP2008546695A (ja)	2005-06-13	2008-12-25	セラヴァンス，インコーポレーテッド	ムスカリン受容体アンタゴニストとして有用なビフェニル化合物
US8429052B2 (en) *	2005-07-19	2013-04-23	Lincoln National Life Insurance Company	Method and system for providing employer-sponsored retirement plan
AU2006305619A1 (en)	2005-10-19	2007-04-26	Ranbaxy Laboratories Limited	Pharmaceutical compositions of muscarinic receptor antagonists
GB0602778D0 (en)	2006-02-10	2006-03-22	Glaxo Group Ltd	Novel compound
US7973055B2 (en) *	2006-03-09	2011-07-05	Theravance, Inc.	Crystalline forms of a biphenyl compound
AR059826A1 (es) *	2006-03-13	2008-04-30	Univ California	Inhibidores de urea conformacionalmente restringidos de epoxido hidrolasa soluble
CN101605784B (zh) *	2007-02-09	2013-04-10	安斯泰来制药株式会社	氮杂桥环化合物
EP2222637A1 (en) *	2007-12-14	2010-09-01	Theravance, Inc.	Amidine-containing compounds useful as muscarinic receptor antagonists
EP2096105A1 (en) *	2008-02-28	2009-09-02	Laboratorios Almirall, S.A.	Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists of the b2 adrenergic receptor
WO2010123766A1 (en) *	2009-04-23	2010-10-28	Theravance, Inc.	DIAMIDE COMPOUNDS HAVING MUSCARINIC RECEPTOR ANTAGONIST AND β2 ADRENERGIC RECEPTOR AGONIST ACTIVITY
EP2528604B1 (en)	2010-01-29	2017-11-22	The Regents of the University of California	Acyl piperidine inhibitors of soluble epoxide hydrolase
EP2630145A1 (en) *	2010-10-20	2013-08-28	Chiesi Farmaceutici S.p.A.	Carbonate derivatives for the treatment of cough
JP6021616B2 (ja) *	2012-12-04	2016-11-09	株式会社アエタスファルマ	３−ピペラジニル−１−ピペリジニル−プロパン誘導体及びそれを含有してなる医薬組成物
KR101514320B1 (ko) *	2013-06-14	2015-04-22	재단법인 의약바이오컨버젼스연구단	신규한 암 예방 또는 치료용 약학적 조성물
MX370140B (es)	2014-06-06	2019-12-03	Astellas Pharma Inc	Derivado de 2-acilaminotiazol o sal del mismo.
HUE068695T2 (hu)	2018-05-08	2025-01-28	Nippon Shinyaku Co Ltd	Azabenzimidazol vegyületek és gyógyszerek
US12065433B2 (en) *	2018-10-24	2024-08-20	Vanderbilt University	Positive allosteric modulators of the muscarinic acetylcholine receptor M1
US20220204497A1 (en) *	2019-03-29	2022-06-30	Medicinal Bioconvergence Research Center	Novel compound having anticancer activity, and method for producing same

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4587046A (en)	1982-05-18	1986-05-06	The Regents Of The University Of California	Drug-carrier conjugates
DE3402060A1 (de)	1984-01-21	1985-08-01	Dr. Karl Thomae Gmbh, 7950 Biberach	Substituierte 5,11-dihydro-6h-dibenz(b,e)azepin-6-one, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US4675326A (en)	1985-05-08	1987-06-23	Gabriel Amitai	Bisquaternary antidotes
DK443489D0 (da) *	1989-09-08	1989-09-08	Ferrosan As	Substituerede urinstofforbindelser, deres fremstilling og anvendelse
PT640081E (pt) *	1992-03-31	2000-05-31	Glaxo Group Ltd	Derivados de fenil-carbamatos e fenil-ureias substituidos sua preparacao e sua utilizacao como antagonistas 5-ht4
CA2123728A1 (en) *	1993-05-21	1994-11-22	Noriyoshi Sueda	Urea derivatives and their use as acat inhibitors
AU7545894A (en) *	1993-09-02	1995-03-22	Yamanouchi Pharmaceutical Co., Ltd.	Carbamate derivative and medicine containing the same
KR970701174A (ko)	1994-02-10	1997-03-17	오노다 마사요시	신규한 카바메이트 유도체 및 이의 의약 조성물(Novel carbamate derivative and medicinal composition containing the same)
US5691323A (en)	1995-05-12	1997-11-25	Merck & Co., Inc.	Muscarine antagonists
DE69615214T2 (de)	1995-10-13	2002-06-27	Banyu Pharmaceutical Co., Ltd.	Substituierte heteroaromatische derivate
WO1998000141A1 (en) *	1996-07-01	1998-01-08	Sepracor, Inc.	Methods and compositions for treating urinary incontinence using enantiomerically enriched (s)-trihexyphenidyl
US6500934B1 (en)	1996-07-24	2002-12-31	Michael Rush Lerner	Bivalent agonists for G-protein coupled receptors
PE92198A1 (es)	1996-08-01	1999-01-09	Banyu Pharma Co Ltd	Derivados de 1,4-piperidina disustituida que contienen fluor
US6062766A (en) *	1997-08-04	2000-05-16	Quixote Corporation	Raised pavement marker
JP2002508366A (ja) *	1997-12-12	2002-03-19	スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー	キノリンピペラジンおよびキノリンピペリジン誘導体、それらの製造方法、ならびに複合的５−ｈｔ１ａ、５−ｈｔ１ｂおよび５−ｈｔ１ｄ受容体アンタゴニストとしてのそれらの用途
US6086881A (en) *	1998-05-15	2000-07-11	Children's Medical Center Corp.	Spatially aligned conjugated composition having a thioether bond linkage
US6066636A (en) *	1998-06-30	2000-05-23	Schering Corporation	Muscarinic antagonists
AU783095B2 (en) *	1999-12-07	2005-09-22	Theravance Biopharma R&D Ip, Llc	Carbamate derivatives having muscarinic receptor antagonist activity
UA73543C2 (uk) *	1999-12-07	2005-08-15	Тераванс, Інк.	Похідні сечовини, фармацевтична композиція та застосування похідного при приготуванні лікарського засобу для лікування захворювання, яке опосередковується мускариновим рецептором
AU2001269906A1 (en) *	2000-06-19	2002-01-02	Zyomyx, Inc.	Methods for immobilizing polypeptides

2000
- 2000-07-12 UA UA2002075566A patent/UA73543C2/uk unknown
- 2000-12-07 HR HR20020574A patent/HRP20020574B1/xx not_active IP Right Cessation
- 2000-12-07 SK SK798-2002A patent/SK7982002A3/sk unknown
- 2000-12-07 EA EA200200646A patent/EA006437B1/ru not_active IP Right Cessation
- 2000-12-07 AT AT04012859T patent/ATE439345T1/de not_active IP Right Cessation
- 2000-12-07 EP EP04012859A patent/EP1457488B1/en not_active Expired - Lifetime
- 2000-12-07 CZ CZ20021830A patent/CZ20021830A3/cs unknown
- 2000-12-07 AU AU19518/01A patent/AU782232B2/en not_active Expired
- 2000-12-07 CA CA002392030A patent/CA2392030C/en not_active Expired - Lifetime
- 2000-12-07 WO PCT/US2000/033155 patent/WO2001042213A1/en not_active Ceased
- 2000-12-07 PL PL00364922A patent/PL364922A1/xx not_active Application Discontinuation
- 2000-12-07 DE DE60042762T patent/DE60042762D1/de not_active Expired - Lifetime
- 2000-12-07 CN CNB008167028A patent/CN1271054C/zh not_active Expired - Lifetime
- 2000-12-07 KR KR1020027007147A patent/KR100748150B1/ko not_active Expired - Lifetime
- 2000-12-07 DE DE60012223T patent/DE60012223T2/de not_active Expired - Lifetime
- 2000-12-07 NZ NZ518722A patent/NZ518722A/en not_active IP Right Cessation
- 2000-12-07 AT AT00982493T patent/ATE271039T1/de not_active IP Right Cessation
- 2000-12-07 EP EP00982493A patent/EP1235803B1/en not_active Expired - Lifetime
- 2000-12-07 ES ES00982493T patent/ES2225275T3/es not_active Expired - Lifetime
- 2000-12-07 YU YU42402A patent/YU42402A/sh unknown
- 2000-12-07 JP JP2001543514A patent/JP2003516391A/ja active Pending
- 2000-12-07 MX MXPA02005602A patent/MXPA02005602A/es active IP Right Grant
- 2000-12-07 BR BR0015963-8A patent/BR0015963A/pt not_active Application Discontinuation
- 2000-12-07 IL IL14928900A patent/IL149289A0/xx active IP Right Grant
- 2000-12-07 ES ES04012859T patent/ES2329785T3/es not_active Expired - Lifetime
- 2000-12-07 US US09/732,514 patent/US6635764B2/en not_active Expired - Lifetime
- 2000-12-07 HK HK03101572.1A patent/HK1049483B/en not_active IP Right Cessation
- 2000-12-07 HU HU0203677A patent/HUP0203677A2/hu unknown
- 2000-12-07 ES ES00983991T patent/ES2243333T3/es not_active Expired - Lifetime
2002
- 2002-04-23 IL IL149289A patent/IL149289A/en unknown
- 2002-04-26 IS IS6362A patent/IS2191B/is unknown
- 2002-06-06 ZA ZA200204557A patent/ZA200204557B/en unknown
- 2002-06-06 NO NO20022683A patent/NO323544B1/no not_active IP Right Cessation
- 2002-06-06 ZA ZA200204553A patent/ZA200204553B/en unknown
2003
- 2003-04-30 US US10/426,270 patent/US20040116706A1/en not_active Abandoned
- 2003-04-30 US US10/426,364 patent/US20040054187A1/en not_active Abandoned

Also Published As

Publication number	Publication date
CA2392030C (en)	2009-08-18
DE60042762D1 (de)	2009-09-24
ATE271039T1 (de)	2004-07-15
ZA200204553B (en)	2003-09-08
KR100748150B1 (ko)	2007-08-09
HK1049483B (en)	2005-02-18
EA006437B1 (ru)	2005-12-29
EP1457488A1 (en)	2004-09-15
ES2243333T3 (es)	2005-12-01
IL149289A (en)	2007-05-15
ES2225275T3 (es)	2005-03-16
WO2001042213A1 (en)	2001-06-14
EA200200646A1 (ru)	2002-12-26
AU1951801A (en)	2001-06-18
NO20022683L (no)	2002-07-02
US20040054187A1 (en)	2004-03-18
BR0015963A (pt)	2002-08-06
MXPA02005602A (es)	2004-09-10
IS2191B (is)	2007-01-15
HK1049483A1 (en)	2003-05-16
ATE439345T1 (de)	2009-08-15
PL364922A1 (en)	2004-12-27
DE60012223T2 (de)	2005-08-25
EP1235803B1 (en)	2004-07-14
YU42402A (sh)	2006-01-16
AU782232B2 (en)	2005-07-14
NO20022683D0 (no)	2002-06-06
US20020049195A1 (en)	2002-04-25
EP1457488B1 (en)	2009-08-12
EP1235803A1 (en)	2002-09-04
CN1407970A (zh)	2003-04-02
CN1271054C (zh)	2006-08-23
ZA200204557B (en)	2003-09-08
DE60012223D1 (de)	2004-08-19
CA2392030A1 (en)	2001-06-14
IL149289A0 (en)	2002-11-10
NO323544B1 (no)	2007-06-11
US6635764B2 (en)	2003-10-21
UA73543C2 (uk)	2005-08-15
SK7982002A3 (en)	2002-12-03
KR20020058083A (ko)	2002-07-12
HUP0203677A2 (hu)	2003-03-28
ES2329785T3 (es)	2009-12-01
HRP20020574A2 (en)	2005-08-31
US20040116706A1 (en)	2004-06-17
HRP20020574B1 (hr)	2007-12-31
NZ518722A (en)	2004-03-26
CZ20021830A3 (cs)	2002-10-16
JP2003516391A (ja)	2003-05-13

Publication	Publication Date	Title
IS6362A (is)	2002-04-26	Úrea (eða þvagefnis) efnasambönd sem hafa múskarín viðtaka mótlyfs virkni
EE200100393A (et)	2002-10-15	Vähivastaste vahenditena kasulikud asendatud bitsüklilised derivaadid
BR9804214A (pt)	1999-12-14	Compostos.
NO20021450L (no)	2002-06-03	Cykliske aminforbindelser som CCR5-antagonister
ES2172864T3 (es)	2002-10-01	2-metoxibenzofenonas fungicidas.
NO20041339L (no)	2004-05-24	Spiro-hydantoin-forbindelser anvendelige som anti-inflammatoriske midler
NO20014412D0 (no)	2001-09-11	Forbindelser nyttige som anti-inflammatoriske midler
DK1204663T3 (da)	2004-02-09	Hidtil ukendte spiroforbindelser med neuropeptid Y antagonistaktivitet
ATE350036T1 (de)	2007-01-15	Tetrahydroquinolin-derivate
MA28393B1 (fr)	2007-01-02	Dérivés de triazole servant d'antagonistes de la vasopressine
ATE374191T1 (de)	2007-10-15	Urea derivate als integrin alpha 4 antagonisten
ATE377602T1 (de)	2007-11-15	Morphinanderivate und ihre medizinische anwendung
BR0206595A (pt)	2004-07-13	Composto, composição farmacêutica, e uso de um composto
HK1045834A1 (zh)	2002-12-13	緩激肽受體拮抗劑
EE200200281A (et)	2003-06-16	Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
IL144720A0 (en)	2002-06-30	Heterocyclic benzenesulphonamide compounds as bradykinine antagonists
DE60218213D1 (de)	2007-03-29	Pyridyloxyalkancarbonsäureamid-derivate verwendbar als fungizide
PT1200400E (pt)	2005-02-28	Derivados de pirrolidino-2,3,4-trion-3-oxina substituidas com eficacia como antagonistas do receptor nmda
DK0896822T3 (da)	2003-06-02	4-aminopyrrol (3,2-d) pyrimidiner som neuropeptide Y receptorantagonister
DE69900297D1 (de)	2001-10-25	Akarizid und insektizid wirksame, substituierte Pyrimidine und Verfahren zu ihrer Herstellung
ITMI20011495A0 (it)	2001-07-12	Sali di calcio ad attivita' citotossica
BR9902096A (pt)	2000-04-11	Pitazóis.
ITMI20020624A0 (it)	2002-03-26	Composizioni ad attivita' biostimolante
DK1085019T3 (da)	2003-05-26	Omoprazolsyntese
ATE286030T1 (de)	2005-01-15	1,4,5,6 -tetrahydropyrimidine-derivative als vitronectin-hemmer